CO5280050A1 - Desnaturalizantes para las sales aminas simpaticomimeticas - Google Patents
Desnaturalizantes para las sales aminas simpaticomimeticasInfo
- Publication number
- CO5280050A1 CO5280050A1 CO99057123A CO99057123A CO5280050A1 CO 5280050 A1 CO5280050 A1 CO 5280050A1 CO 99057123 A CO99057123 A CO 99057123A CO 99057123 A CO99057123 A CO 99057123A CO 5280050 A1 CO5280050 A1 CO 5280050A1
- Authority
- CO
- Colombia
- Prior art keywords
- sympathomimetic amine
- denaturing
- inhibitor
- amine salts
- sympathomimetic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/765—Polymers containing oxygen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Abstract
Una composición farmacéutica caracterizada porque comprende:una sal ácida de una amina simpaticomimética; al menos un inhibidor de combinación, donde dicho inhibidor de combinación es un compuesto que interfiere con el aislamiento de la amina simpaticomimética y con la conversión de dicha amina simpaticomimética en otros compuestos farmacológicamente activos. Dicho inhibidor de combinación está presente en cantidad suficiente (la relación de las sales de una amina simpaticomimética con los componentes del inhibidor es de 1:100 a 100:1; preferentemente 1:10 a 10:1; más preferentemente 1:5 a 5:1), sin alterar significativamente la liberación de dicha amina simpaticomimética de dicha composición farmacéutica en comparación con la composición no desnaturalizada.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US9971298P | 1998-09-10 | 1998-09-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO5280050A1 true CO5280050A1 (es) | 2003-05-30 |
Family
ID=22276270
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO99057123A CO5280050A1 (es) | 1998-09-10 | 1999-09-09 | Desnaturalizantes para las sales aminas simpaticomimeticas |
Country Status (22)
Country | Link |
---|---|
US (4) | US6359011B1 (es) |
EP (1) | EP1112089A1 (es) |
JP (1) | JP2002524534A (es) |
KR (1) | KR20010075021A (es) |
CN (1) | CN1201822C (es) |
AR (1) | AR032730A1 (es) |
AU (2) | AU771194B2 (es) |
BR (1) | BR9913575A (es) |
CA (1) | CA2339354A1 (es) |
CO (1) | CO5280050A1 (es) |
CR (1) | CR6106A (es) |
GT (1) | GT199900148A (es) |
HK (1) | HK1039898A1 (es) |
HN (1) | HN1999000156A (es) |
MY (1) | MY117971A (es) |
NZ (1) | NZ510012A (es) |
PA (1) | PA8481601A1 (es) |
PE (1) | PE20001034A1 (es) |
SV (1) | SV1999000148A (es) |
TW (1) | TW550071B (es) |
UY (1) | UY25702A1 (es) |
WO (1) | WO2000015261A1 (es) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GT199900148A (es) * | 1998-09-10 | 2001-02-28 | Desnaturalizantes para las sales aminas simpaticomimeticas. | |
AU7105501A (en) * | 2000-07-17 | 2002-01-30 | Yamanouchi Pharma Co Ltd | Pharmaceutical composition improved in peroral absorbability |
ATE382335T1 (de) * | 2000-11-30 | 2008-01-15 | Vectura Ltd | Verfahren zur vorbereitung von mikropartikeln zur verwendung in pharmazeutischen zusammensetzungen zur inhalation |
ITMI20021074A1 (it) * | 2002-05-20 | 2003-11-20 | Actimex S R L | Composizione ternaria comprendente una sostanza attiva e processo di comacinazione per la sua preparazione |
US7776314B2 (en) | 2002-06-17 | 2010-08-17 | Grunenthal Gmbh | Abuse-proofed dosage system |
DE10361596A1 (de) | 2003-12-24 | 2005-09-29 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
DE102005005446A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Bruchfeste Darreichungsformen mit retardierter Freisetzung |
US7201920B2 (en) | 2003-11-26 | 2007-04-10 | Acura Pharmaceuticals, Inc. | Methods and compositions for deterring abuse of opioid containing dosage forms |
US20050220877A1 (en) * | 2004-03-31 | 2005-10-06 | Patel Ashish A | Bilayer tablet comprising an antihistamine and a decongestant |
DE102004032049A1 (de) | 2004-07-01 | 2006-01-19 | Grünenthal GmbH | Gegen Missbrauch gesicherte, orale Darreichungsform |
DE102004045037A1 (de) * | 2004-09-15 | 2006-03-16 | Basf Ag | Pharmazeutische Darreichungsformen mit erschwerter Extrahierbarkeit eines Sympathomimetikums aus der Darreichungsform |
DE102005005449A1 (de) | 2005-02-04 | 2006-08-10 | Grünenthal GmbH | Verfahren zur Herstellung einer gegen Missbrauch gesicherten Darreichungsform |
EP1978940B1 (en) * | 2006-01-19 | 2010-12-29 | Dow Global Technologies Inc. | Biologically active composition comprising ethylcellulose |
US9238073B2 (en) | 2006-04-12 | 2016-01-19 | Wyeth Llc | Pharmaceutical composition containing sympathomimetic amine salt and co-distillable additive |
US8273798B2 (en) * | 2007-06-04 | 2012-09-25 | Shear Kershman Laboratories | Tamper resistant lipid-based oral dosage form for opioid agonists |
US20100288665A1 (en) * | 2007-07-23 | 2010-11-18 | Kingsway Pharmaceuticals Inc. | Therapeutic formulations for the treatment of cold and flu-like symptoms |
ES2406939T3 (es) | 2007-10-19 | 2013-06-10 | Otsuka Pharmaceutical Co., Ltd. | Preparación farmacéutica de matriz sólida |
JP2012533585A (ja) | 2009-07-22 | 2012-12-27 | グリュネンタール・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング | 酸化感受性オピオイドのための不正使用防止剤形 |
ES2569925T3 (es) * | 2009-09-30 | 2016-05-13 | Acura Pharmaceuticals, Inc. | Métodos y composiciones de disuasión del abuso |
US20130028972A1 (en) | 2011-07-29 | 2013-01-31 | Grunenthal Gmbh | Tamper-resistant tablet providing immediate drug release |
AR087360A1 (es) | 2011-07-29 | 2014-03-19 | Gruenenthal Gmbh | Tableta a prueba de manipulacion que proporciona liberacion de farmaco inmediato |
WO2013036567A2 (en) * | 2011-09-07 | 2013-03-14 | Johnson Brent A | Methods, compositions, and compounds for the reduction of illegal methamphetamine production |
US20150238615A1 (en) * | 2011-12-12 | 2015-08-27 | Leonard Mackles | Denaturants for sympathomimetic amines |
EP2880011A4 (en) * | 2012-08-01 | 2016-03-23 | Acura Pharmaceuticals Inc | STABILIZATION OF SYNTHESIS SYSTEMS OF METHAMPHETAMINE IN SINGLE PREGNANCY |
RU2673818C2 (ru) | 2012-11-30 | 2018-11-30 | Экьюра Фармасьютикалз, Инк. | Саморегулируемое высвобождение фармацевтического ингредиента |
NZ716482A (en) * | 2013-07-03 | 2017-07-28 | Acura Pharmaceuticals Inc | Methods and compositions for deterring abuse |
CN105682643B (zh) | 2013-07-12 | 2019-12-13 | 格吕伦塔尔有限公司 | 含有乙烯-醋酸乙烯酯聚合物的防篡改剂型 |
CA2931553C (en) | 2013-11-26 | 2022-01-18 | Grunenthal Gmbh | Preparation of a powdery pharmaceutical composition by means of cryo-milling |
US9642811B2 (en) | 2014-03-26 | 2017-05-09 | Sun Pharma Advanced Research Company Ltd. | Abuse deterrent immediate release biphasic matrix solid dosage form |
US11103581B2 (en) | 2015-08-31 | 2021-08-31 | Acura Pharmaceuticals, Inc. | Methods and compositions for self-regulated release of active pharmaceutical ingredient |
US10842750B2 (en) * | 2015-09-10 | 2020-11-24 | Grünenthal GmbH | Protecting oral overdose with abuse deterrent immediate release formulations |
TW202002957A (zh) | 2018-02-09 | 2020-01-16 | 德商歌林達有限公司 | 包含轉化抑制劑之麻黃素及其衍生物之抗損壞調配物 |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3169092A (en) | 1963-09-26 | 1965-02-09 | Richardson Merrell Inc | Stabilization of amines by tartrazine and bisulfite |
US3546142A (en) * | 1967-01-19 | 1970-12-08 | Amicon Corp | Polyelectrolyte structures |
US3773920A (en) * | 1971-07-14 | 1973-11-20 | Nikken Chemicals Co Ltd | Sustained release medicinal composition |
GB1593261A (en) | 1976-07-23 | 1981-07-15 | Inveresk Res Int | Controlled release suppository |
RO68771A2 (ro) * | 1976-08-25 | 1980-08-15 | Intreprinderea De Medicamente,Ro | Unguent antipruriginos si sicativ |
SU1146046A1 (ru) | 1983-11-11 | 1985-03-23 | Центральный Ордена Ленина Институт Усовершенствования Врачей | Состав дл ретракции десны |
US4493827A (en) | 1983-11-14 | 1985-01-15 | Ronald Valle | Method of inducing sleep |
US4657757A (en) | 1985-03-29 | 1987-04-14 | Schering Corporation | Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate |
US4601894A (en) * | 1985-03-29 | 1986-07-22 | Schering Corporation | Controlled release dosage form comprising acetaminophen, pseudoephedrine sulfate and dexbrompheniramine maleate |
US4800087A (en) * | 1986-11-24 | 1989-01-24 | Mehta Atul M | Taste-masked pharmaceutical compositions |
US5026560A (en) * | 1987-01-29 | 1991-06-25 | Takeda Chemical Industries, Ltd. | Spherical granules having core and their production |
US4894239A (en) | 1987-06-02 | 1990-01-16 | Takeda Chemical Industries, Ltd. | Sustained-release preparation and production thereof |
ZA904021B (en) | 1989-11-24 | 1991-02-27 | Van Der Linde Leon | Slimming preparations |
CA2068402C (en) | 1991-06-14 | 1998-09-22 | Michael R. Hoy | Taste mask coatings for preparation of chewable pharmaceutical tablets |
US5407686A (en) | 1991-11-27 | 1995-04-18 | Sidmak Laboratories, Inc. | Sustained release composition for oral administration of active ingredient |
US5518730A (en) * | 1992-06-03 | 1996-05-21 | Fuisz Technologies Ltd. | Biodegradable controlled release flash flow melt-spun delivery system |
JP3733140B2 (ja) | 1993-06-04 | 2006-01-11 | ワーナー−ランバート・コンパニー | 多重作用性風邪/鼻づまり製剤 |
US5543405A (en) * | 1993-10-22 | 1996-08-06 | Keown; Wendy J. | Composition and method for weight reduction and long term management of obesity |
AUPM814994A0 (en) | 1994-09-14 | 1994-10-06 | Sterling Winthrop Inc. | Codeine-containing formulations |
US5529783A (en) * | 1994-12-19 | 1996-06-25 | Mcneil-Ppc, Inc. | Rotor granulation and coating of acetaminophen, pseudoephedrine, chlorpheniramine, and, optionally dextromethorphan |
US5626878A (en) | 1995-01-10 | 1997-05-06 | Warner Lambert Company | Reduction of electrostatic forces between magnesium trisilicate adsorbates |
PT894010E (pt) | 1996-04-10 | 2003-11-28 | Warner Lambert Co | Desnaturantes para sais de amina simpaticomimetica |
GT199900148A (es) * | 1998-09-10 | 2001-02-28 | Desnaturalizantes para las sales aminas simpaticomimeticas. |
-
1999
- 1999-09-07 GT GT199900148A patent/GT199900148A/es unknown
- 1999-09-08 MY MYPI99003873A patent/MY117971A/en unknown
- 1999-09-08 US US09/391,739 patent/US6359011B1/en not_active Expired - Lifetime
- 1999-09-09 NZ NZ510012A patent/NZ510012A/xx unknown
- 1999-09-09 SV SV1999000148A patent/SV1999000148A/es not_active Application Discontinuation
- 1999-09-09 KR KR1020017003081A patent/KR20010075021A/ko not_active Application Discontinuation
- 1999-09-09 PE PE1999000908A patent/PE20001034A1/es not_active Application Discontinuation
- 1999-09-09 BR BR9913575-2A patent/BR9913575A/pt not_active Application Discontinuation
- 1999-09-09 CO CO99057123A patent/CO5280050A1/es not_active Application Discontinuation
- 1999-09-09 JP JP2000569845A patent/JP2002524534A/ja active Pending
- 1999-09-09 WO PCT/US1999/020708 patent/WO2000015261A1/en not_active Application Discontinuation
- 1999-09-09 AU AU59157/99A patent/AU771194B2/en not_active Ceased
- 1999-09-09 PA PA19998481601A patent/PA8481601A1/es unknown
- 1999-09-09 AR ARP990104527A patent/AR032730A1/es unknown
- 1999-09-09 CR CR6106A patent/CR6106A/es not_active Application Discontinuation
- 1999-09-09 UY UY25702A patent/UY25702A1/es not_active Application Discontinuation
- 1999-09-09 HN HN1999000156A patent/HN1999000156A/es unknown
- 1999-09-09 CN CNB998107565A patent/CN1201822C/zh not_active Expired - Fee Related
- 1999-09-09 EP EP99946837A patent/EP1112089A1/en not_active Withdrawn
- 1999-09-09 CA CA002339354A patent/CA2339354A1/en not_active Abandoned
- 1999-09-10 TW TW088115613A patent/TW550071B/zh not_active IP Right Cessation
-
2001
- 2001-11-20 US US09/996,438 patent/US20020082304A1/en not_active Abandoned
-
2002
- 2002-02-26 HK HK02101442.0A patent/HK1039898A1/zh unknown
-
2004
- 2004-06-18 AU AU2004202702A patent/AU2004202702B2/en not_active Ceased
-
2005
- 2005-07-20 US US11/186,681 patent/US20050256194A1/en not_active Abandoned
-
2006
- 2006-06-02 US US11/445,967 patent/US20060216268A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20020082304A1 (en) | 2002-06-27 |
NZ510012A (en) | 2002-11-26 |
CN1201822C (zh) | 2005-05-18 |
US20060216268A1 (en) | 2006-09-28 |
BR9913575A (pt) | 2001-05-22 |
CA2339354A1 (en) | 2000-03-23 |
CN1316911A (zh) | 2001-10-10 |
US20050256194A1 (en) | 2005-11-17 |
CR6106A (es) | 2003-12-05 |
EP1112089A1 (en) | 2001-07-04 |
GT199900148A (es) | 2001-02-28 |
MY117971A (en) | 2004-08-30 |
HK1039898A1 (zh) | 2002-05-17 |
WO2000015261A1 (en) | 2000-03-23 |
US6359011B1 (en) | 2002-03-19 |
AU2004202702A1 (en) | 2004-07-15 |
UY25702A1 (es) | 1999-11-17 |
PE20001034A1 (es) | 2000-10-18 |
TW550071B (en) | 2003-09-01 |
AU2004202702B2 (en) | 2007-11-22 |
SV1999000148A (es) | 2000-09-11 |
PA8481601A1 (es) | 2001-04-30 |
AR032730A1 (es) | 2003-11-26 |
AU771194B2 (en) | 2004-03-18 |
AU5915799A (en) | 2000-04-03 |
JP2002524534A (ja) | 2002-08-06 |
HN1999000156A (es) | 2003-08-01 |
KR20010075021A (ko) | 2001-08-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO5280050A1 (es) | Desnaturalizantes para las sales aminas simpaticomimeticas | |
AR062931A2 (es) | Compuestos que se enlazan a y activan un receptor de la trombopoyetina , composicones farmaceuticas que los contienen y su uso para la preparacion de medicamentos | |
AR008377A1 (es) | Un compuesto derivado de la 3-aroilbencilpiridazinona, una composicion farmaceutica particularmente para el tratamiento de enfermedades inflamatorias o autoinmunes que contiene dicho compuesto | |
ES2164720T3 (es) | Derivados de piperidina como agentes anticolinergicos. | |
AR010634A1 (es) | Composicion farmaceutica en forma de una solucion para la administracion de inhibidores de proteasa hiv | |
UY25242A1 (es) | Inhibidores de benzotiazol de la proteína tirosina cinasa | |
ES2185606T3 (es) | Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma. | |
AR023101A1 (es) | Un proceso mejorado para la preparacion de sales no higroscopicas de l(-)-carnitina | |
GT200000226A (es) | Inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias. | |
PE20050130A1 (es) | Compuestos organicos | |
UY26199A1 (es) | Nuevos derivados de benceno, un procedimiento para su preparación y las composiciones farmacéuticas que los contienen | |
BR9912029A (pt) | Compostos reacionais de amina compreendendo um ou mais ingredientes ativos | |
ES2192234T3 (es) | Composiciones farmaceuticas parenterales conteniendo sales de amonioalquilo de acidos 2-arilpropionicos. | |
AR031473A1 (es) | Intensificadores de gaba en el tratamiento de enfermedades relacionadas con una reducida actividad neuroesteroide | |
ATE286038T1 (de) | Verbindungen mit sulfonsäure-amidgruppe | |
ES2191090T3 (es) | Nuevos compuestos heterociclicos. | |
BR0204678A (pt) | Inibidor de nf-kb contendo derivado de ácido benzóico substituìdo como ingrediente ativo | |
PA8426801A1 (es) | Composiciones farmaceuticas para el tratamiento de la rinitis. | |
MX9306311A (es) | Compuestos antagonistas del receptor de 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que los contienen | |
AR014964A1 (es) | Derivados de indol, composiciones farmaceuticas que los contienen, agentes para reducir la presion intraocular, tratar glaucoma e hipertension ocular, usosen la fabricacion de composiciones farmaceuticas y procedimiento de fabricacion de dichas composiciones | |
CO5011084A1 (es) | Composiciones y metodos para tratar trastornos respiratorios | |
ES2179523T3 (es) | Metodo para aumentar la biodisponibilidad de la fexofenadina y sus derivados. | |
AR008236A1 (es) | Forma cristalina anhidra del clorhidrato de acido r(-)-n-(4,4-di(3- metiltien-2-il)but-3-enil)-nipecotico, una composicion farmaceutica y el uso de dicha sal cristalina para la preparacion de una composicion farmaceutica | |
ES2043943T3 (es) | Procedimiento para la preparacion de compuestos con actividad analgesica central. | |
BR0115616A (pt) | Preparação de inibidores de permutadores sódio-hidrogênio do tipo 1 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Application granted | ||
FD | Application lapsed |